What Gasmotin treats: main uses and benefits

Gasmotin, known by its generic name mosapride citrate, is a gastroprokinetic agent primarily used to improve digestive motility. It works by enhancing the movement of the stomach and intestines, which helps facilitate the passage of food through the digestive tract.

Primary Indications

The medication is most commonly used to manage gastrointestinal symptoms associated with various digestive conditions. These include:

• Chronic Gastritis: Gasmotin is used to relieve symptoms of chronic gastritis, such as a feeling of fullness, upper abdominal pain, nausea, and vomiting.
• Gastroesophageal Reflux Disease (GERD): It may be utilized as part of a treatment plan for heartburn and the regurgitation of gastric acid by promoting gastric emptying and reducing the backflow of stomach contents into the esophagus.
• Functional Dyspepsia: The drug helps address indigestion that occurs without an obvious structural cause, focusing on symptoms like early satiety and bloating.

Benefits and Mechanism of Action

The clinical benefit of Gasmotin stems from its role as a selective 5-HT4 receptor agonist. By stimulating these receptors, it increases the release of acetylcholine in the gastrointestinal nerve endings, which results in several physiological advantages:

• Enhanced Gastric Emptying: It speeds up the rate at which food leaves the stomach and enters the small intestine.
• Improved Coordination: It helps synchronize the contractions of the digestive muscles, leading to more efficient digestion.
• Symptom Reduction: By addressing the underlying issue of slow motility, it helps alleviate the physical discomfort and pressure often associated with delayed digestion.

Regulatory References

1. Pharmaceuticals and Medical Devices Agency (PMDA)

Who Can and Cannot Use Gasmotin?

Eligibility for Gasmotin (Mosapride) is strictly defined by regulatory documents, distinguishing between populations that must not use the medicine (contraindications) and those requiring restricted use or special caution.

Prohibited Use (Contraindications)

The medicine is contraindicated and must not be used in individuals with specific physical compromises of the digestive tract, including gastrointestinal hemorrhage (bleeding), mechanical obstruction, or perforation. Use is also prohibited for patients with a known hypersensitivity to Mosapride Citrate or its excipients, or those with rare hereditary problems such as lactose malabsorption.

Restricted or Conditional Use

Use is limited or requires caution in several special populations. The medicine is not established and generally not recommended for children or adolescents due to insufficient clinical data.

Older adults (geriatric patients) and patients with hepatic impairment (liver disease) or renal impairment (kidney disease) must use the medicine with caution and require close monitoring due to reduced physiological function. For pregnant women and nursing mothers, use is restricted: safety has not been established in pregnancy, and if use is essential during lactation, discontinuation of breastfeeding is required.

Gasmotin (mosapride) may interact with certain medicines, which can change its effectiveness or lead to higher levels of the drug in the body. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and supplements you are currently taking.

Documented Drug Interactions

Interacting Product Category	Specific Examples Listed	Effect and Clinical Note
Anticholinergic Agents	Atropine sulfate, butylscopolamine bromide	Concomitant use may decrease the therapeutic effect of Gasmotin. This is due to a clash in their mechanisms of action, as anticholinergic agents oppose the activation of cholinergic nerves, which is how Gasmotin promotes gut movement.
Antibiotics	Erythromycin	Concomitant use increases the maximum blood concentration left(C max

ight) and prolongs the half-life left(t1/2 ight) of mosapride in the bloodstream. This is a pharmacokinetic interaction suggesting inhibition of mosapride's metabolism. |

Administration and Risk

Both of these documented interaction types are generally classified by regulatory bodies as requiring careful administration or use with caution. For anticholinergic agents, official guidance may advise precautions, such as separating the administration times of the drugs, to minimize the risk of reduced effectiveness. The concurrent use of Erythromycin is noted for increasing the systemic exposure of mosapride, which necessitates monitoring.

How Gasmotin Works: Mechanism of Action

Selective 5-HT4 Receptor Targeting

Gasmotin (Mosapride) initiates its pharmacodynamic action by selectively binding to and activating 5-HT4 receptors located within the enteric nervous system of the gastrointestinal (GI) tract. This targeted interaction modulates signaling patterns within pathways that govern GI motor function, establishing the primary molecular step of its mechanism.

Acetylcholine Release and Signal Amplification

Activation of the 5-HT4 receptors triggers a crucial mechanistic cascade: the local release of acetylcholine (ACh) from nerve endings in the myenteric plexus. This amplification modifies the signal responsible for stimulating GI smooth muscle contraction, adjusting the processes mediated by specific neural signaling patterns in the GI wall.

Modulating Gastrointestinal Motility

The resulting physiological effect of increased local acetylcholine activity is the enhancement of coordinated smooth muscle contractions and relaxation. This mechanism results in the acceleration of smooth muscle contraction and propagation velocity. The resultant changes in motility reflect the adjusted activity within the targeted motor pathways.

Official Administration Guidelines

Gasmotin is prescribed for oral administration only, available as tablets (e.g., 5 mg strength). The standard regimen for managing gastrointestinal symptoms is 5 mg taken 3 times a day (TID), resulting in a total daily dose of 15 mg. This regimen provides flexibility, as the dose may be administered either before or after meals. A distinct, higher-dose protocol is utilized for procedural use as an adjunct during preparation for diagnostic procedures, such as a barium enema examination.

Population and Duration Rules

Administration protocols address specific population use. For older adults, careful administration is indicated, noting that a reduced total daily dose, such as 7.5 mg, may be appropriate if physiological function is diminished. Conversely, use in pediatric patients is generally avoided as adequate safety and efficacy have not been clinically established. The administration protocol includes a high-level constraint: the drug must not be administered continuously for a long period if no positive effect is observed within an initial course of treatment.

Administration Principles

The prescribed dosing frequency defines a multiple-times-daily schedule. A key instruction is provided for missed doses: the general principle is to take the missed dose as soon as remembered, but if the time for the next scheduled dose is near, the patient must skip the missed dose entirely to prevent taking two doses simultaneously. These instructions structure the standardized approach to using the medicine.

Gasmotin: Recent Clinical Evidence

---

Evidence for Symptom Management in Functional Dyspepsia and Chronic Gastritis

Research has examined Gasmotin in adult patients with Functional Dyspepsia (FD) and Chronic Gastritis. The studies monitored symptom patterns over short-term periods, typically four to twelve weeks, focusing on outcomes related to physical discomfort such as post-meal fullness, nausea, and abdominal pain. The research examined patient-reported relief rates and the functional outcome of gastric emptying time.

Studies report various patterns of change in symptom scores. However, evidence indicates that results were mixed in some large reviews, with unexplained heterogeneity noted across different trials. This means that certainty remains low regarding a singular conclusion across all patient groups, and long-term effects are not fully established.

---

Research on Post-Surgical Recovery of Gut Motility

Studies explored the use of Gasmotin in research contexts involving temporary physiological imbalance following major abdominal surgery. This evidence primarily comes from Randomized Controlled Trials (RCTs) conducted on adult patients. The research examined objective functional measures of gut recovery, such as the time to first passage of flatus and the time to first detectable bowel sound in the immediate postoperative period.

The studies reported measured differences in the time required for patients to reach these specific functional milestones when compared to the control group. Evidence for this specific application is limited, as few studies have provided data following a wide range of complex surgical procedures, and some trials used modest sample sizes.

---

Research Gaps and Uncertainties

Overall, the quality of evidence varies across studies. Data for certain groups remain insufficient. The results apply only to the adult populations studied, and information is limited for key special populations, such as pediatric patients. Furthermore, research relying on low-quality study designs (such as for adjunctive use in diagnostic procedures) necessitates further, more rigorous investigation.

Key Studies & References

1. Mosapride Citrate Hydrate (Gasmotin®) - Product Information (PMDA Index 36205)

Common questions about Gasmotin (FAQ)

---

Q: Are there any official warnings about Gasmotin and driving?

A: Yes, official safety advice includes a direct warning. Since the medicine may cause dizziness and sleepiness, patients are officially cautioned that they should not drive or operate heavy machinery until they are certain of how the medicine affects their alertness.

Q: Can Gasmotin be crushed or split?

A: Instructions for use in the product labeling state that the tablets should be swallowed whole with water. Patients are advised not to crush, break, or chew the Gasmotin tablets before swallowing.

Q: Can I take Gasmotin if I'm already taking supplements?

A: Regulatory documents advise patients to inform their healthcare provider about all medicines, including over-the-counter drugs, vitamins, and dietary supplements, before starting Gasmotin. This general caution is given because some herbal products or supplements may carry a risk of interaction with the medicine or affect how it works in the body.

Q: Are there any foods or drinks I should avoid while taking Gasmotin?

A: Official safety advice provides specific cautions regarding certain drinks. Patients are generally advised to avoid consuming alcohol and grapefruit juice while using Mosapride, as these substances may potentially lead to undesirable effects or alter the medicine's activity.

Q: Are there any known interactions between Gasmotin and heart medications?

A: Official documents detail potential interactions with certain heart medications, particularly some anti-arrhythmics such as amiodarone and sotalol. These specific documented interactions may require the use of caution or an adjustment to the medication regimen.

Q: Are there different strengths of Gasmotin available?

A: Official prescribing details indicate that Gasmotin is available in multiple tablet strengths, typically including 2.5 mg and 5 mg. The 5 mg tablet is commonly referenced in documents describing the standard regimen. The medicine may also be used in a distinct, higher-dose protocol for specific diagnostic preparation procedures.

Q: Does Gasmotin affect blood pressure?

A: While Gasmotin primarily affects the gut, official warnings indicate a potential for cardiovascular effects in certain individuals. For this reason, patients with a history of heart conditions are noted in regulatory documents as needing to use the medicine with caution and may require careful monitoring of their heart function.

Q: Does Gasmotin cause drowsiness or affect alertness?

A: Product labeling warns that Gasmotin may potentially cause dizziness and sleepiness. Due to these possible effects on the central nervous system, patients are officially advised to be cautious and should not drive or operate machinery until they are certain of how the medicine affects their alertness.

Q: Does Gasmotin interact with alcohol, according to product labeling?

A: Official product labeling advises patients to avoid the consumption of alcohol while taking Gasmotin. Alcohol consumption is noted to potentially worsen side effects like drowsiness and may lead to other undesirable effects.

Q: Does Gasmotin require a special diet to work properly?

A: Regulatory-sourced advice for managing the underlying condition often includes lifestyle adjustments. Recommendations may involve eating smaller, more frequent meals and avoiding foods such as high-fat, spicy, or acidic items. This dietary advice is intended to support the medicine's goal of symptom relief.

Q: Does taking Gasmotin affect lab test results?

A: The safety profile notes that certain laboratory tests may show temporary changes. Specifically, temporary elevations in liver enzyme levels (AST and ALT) are listed as a possible common effect. Official product information typically does not detail whether other common lab markers are affected.

Q: How long does Gasmotin stay in your system after stopping?

A: Studies indicate the drug is eliminated relatively quickly from the body. The reported half-life—the time it takes for the concentration of the medicine in the blood to decrease by half—is approximately 2 hours after a single intake. This information is based on pharmacokinetic data cited in official documents.

Q: How long does it typically take for Gasmotin to start working?

A: The medicine is quickly absorbed into the body after it is taken orally. Pharmacokinetic studies show that the time to reach the highest concentration in the blood is typically less than one hour. This rapid entry into the system is the initial step toward the drug starting its action.

Q: If I have allergies, can I still take Gasmotin?

A: Official restrictions for Gasmotin focus on a specific allergy to the medicine itself. It is contraindicated if a patient has a known hypersensitivity to the active ingredient, Mosapride Citrate, or any of the inactive ingredients (excipients). General allergies to things like food or pollen are not listed as a contraindication for its use.

Q: Is Gasmotin commonly used in other countries?

A: According to regulatory and research materials, Gasmotin (Mosapride) is commonly available and used in countries such as Japan and several other Asian regions. However, this medicine is not marketed or available in the United States or most European countries.

Q: Is Gasmotin considered a high-risk medication?

A: Regulatory documents do not categorize the medicine using the term “high-risk.” However, they clearly state that it is contraindicated for patients with structural issues like gastrointestinal hemorrhage or perforation. Furthermore, product information details a rare, serious risk of liver disorders, particularly if the medicine is administered for a prolonged time without clear benefit.

Q: Is Gasmotin known by any other name internationally?

A: The active ingredient in this medicine is Mosapride. According to regulatory and international drug information, Gasmotin is a brand name for this compound. It is often referred to by its generic name, Mosapride Citrate, especially as it is primarily available in Japan and some other Asian countries, but not typically in the US or Europe.

Q: Is Gasmotin a stimulant?

A: Gasmotin is officially classified as a gastroprokinetic agent. This pharmacological class is designed to regulate and enhance the motor function of the digestive tract. While it works by stimulating nerves in the gut to promote movement, regulatory sources do not typically refer to it as a stimulant in the common sense associated with central nervous system effects.

Q: Is it normal to feel a change in bowel habits when starting Gasmotin?

A: Yes, a change in bowel habits may be expected when using Gasmotin. The medicine's purpose is to improve motility (movement) in the digestive system. Consistent with this action, diarrhea or loose stools are listed in official documents as common side effects.

Q: Is it possible to develop a tolerance to Gasmotin?

A: Research cited in product documents has examined how the body responds to repeated use. In animal studies, the effect of Mosapride in enhancing gut emptying was observed to decrease after one week of continuous administration. This finding is included in product documents as evidence suggesting that the effect on gut emptying may be less pronounced with continuous use.

Q: What are the signs of a serious side effect from Gasmotin?

A: Official product information notes the rare potential for serious liver issues. Official documentation advises that certain symptoms, such as generalized fatigue or jaundice (yellowness in the skin and the whites of the eyes), should prompt immediate consultation with a healthcare professional. These are listed as symptoms potentially associated with severe hepatic (liver) dysfunction.

Q: What should I do if I notice an unexpected side effect from Gasmotin?

A: Official instructions advise that any unexpected or concerning side effects should be reported to a doctor or pharmacist for guidance. This ensures that the patient receives proper guidance and that the adverse event is addressed promptly.

How to Store and Dispose of Gasmotin?

Gasmotin (Mosapride Citrate) must be stored according to specific regulatory requirements to maintain its stability.

Storage Conditions

The tablets must be stored at temperatures not exceeding 30°C, generally within a room temperature range of 1 C to 30 C. It is mandatory to store the medicine protected from moisture, and kept away from direct sunlight and heat. For child safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance states that unused or remaining Gasmotin must be discarded and not given to others. If the proper disposal procedure is unknown, patients should consult the pharmacy or medical institution where the product was received.